Literature DB >> 7913160

Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.

N McClure1, D L Healy, P A Rogers, J Sullivan, L Beaton, R V Haning, D T Connolly, D M Robertson.   

Abstract

We investigated the role of vascular endothelial growth factor (VEGF) in ovarian hyperstimulation syndrome (OHSS). Two similar peaks of permeability activity were seen in OHSS ascites and liver ascites spiked with recombinant human VEGF (rhVEGF); no activity was seen in control liver ascites. Incubation with rhVEGF antiserum decreased activity in the two OHSS peaks by 79% and 65% and the two spiked liver peaks by 49% and 50%. Control serum produced 24% and 27%, and 17% and 0% reductions, respectively. This is evidence that the major capillary permeability agent in OHSS ascites fluid is VEGF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913160     DOI: 10.1016/s0140-6736(94)93001-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

Review 1.  Vascular growth factors in cerebral ischemia.

Authors:  S D Croll; S J Wiegand
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Cancer in women after assisted reproductive technology.

Authors:  Barbara Luke; Morton B Brown; Logan G Spector; Stacey A Missmer; Richard E Leach; Melanie Williams; Lori Koch; Yolanda Smith; Judy E Stern; G David Ball; Maria J Schymura
Journal:  Fertil Steril       Date:  2015-08-10       Impact factor: 7.329

Review 4.  Understanding ovarian hyperstimulation syndrome.

Authors:  Anne Delbaere; Guillaume Smits; Anne De Leener; Sabine Costagliola; Gilbert Vassart
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

5.  Meigs' syndrome: a rare cause of recurrent pleural effusion in scleroderma.

Authors:  Feng Su; Kristopher W Cummings; Hannah Krigman; Prabha Ranganathan
Journal:  Rheumatol Int       Date:  2012-04-27       Impact factor: 2.631

6.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

7.  Granulocyte colony-stimulating factor in conjunction with vascular endothelial growth factor maintains primordial follicle numbers in transplanted mouse ovaries.

Authors:  Malgorzata E Skaznik-Wikiel; Rakesh K Sharma; Kaisa Selesniemi; Ho-Joon Lee; Jonathan L Tilly; Tommaso Falcone
Journal:  Fertil Steril       Date:  2011-01-26       Impact factor: 7.329

Review 8.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

Review 9.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.